Pfizer (NYSE:PFE) Issues FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: Pfizer forecasted EPS of 2.80–3.00 (consensus 2.97) and revenue of $59.5B–$62.5B (consensus $61.3B).
• Pfizer beat Q1 estimates with EPS $0.75 (consensus $0.71) and revenue $14.45B (consensus $13.84B), and highlighted R&D/pipeline momentum including FDA approval for VEPPANU.
• The company declared a quarterly dividend of $0.43 (annualized $1.72) for a 6.5% yield, while its dividend payout ratio is reported at 126.47%.

Pfizer (NYSE:PFE - Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 2.800-3.000 for the period, compared to the consensus EPS estimate of 2.970. The company issued revenue guidance of $59.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.3 billion.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. BMO Capital Markets reissued an "outperform" rating and issued a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. Barclays began coverage on Pfizer in a research report on Thursday, February 19th. They issued an "underweight" rating and a $25.00 target price on the stock. UBS Group increased their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Monday, April 13th. Royal Bank Of Canada reissued an "underperform" rating and issued a $25.00 price objective on shares of Pfizer in a report on Monday, April 20th. Finally, HSBC upped their price target on Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and an average target price of $28.74.

Pfizer Trading Down 0.1%

Shares of PFE stock opened at $26.31 on Tuesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The stock has a market capitalization of $149.61 billion, a P/E ratio of 19.35 and a beta of 0.35. The company has a 50 day moving average price of $27.17 and a 200 day moving average price of $26.11. Pfizer has a fifty-two week low of $21.97 and a fifty-two week high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.71 by $0.04. The firm had revenue of $14.45 billion during the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date is Friday, May 8th. Pfizer's dividend payout ratio (DPR) is presently 126.47%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported strong first-quarter results and reaffirmed its full‑year 2026 guidance, with CEO Albert Bourla highlighting R&D progress and pipeline momentum — a direct support for near‑term revenue visibility and investor confidence. Read More.
• Positive Sentiment: Q1 profit topped Wall Street estimates, helped by sustained demand for legacy drug Eliquis — showing Pfizer can still drive cash flow from established franchises even as it builds newer growth drivers. Read More.
• Positive Sentiment: Pfizer and Arvinas won FDA approval for VEPPANU (vepdegestrant), a first‑of‑its‑kind therapy for ESR1‑mutated advanced breast cancer — a meaningful commercial and strategic win for Pfizer’s oncology portfolio. Read More.
• Neutral Sentiment: Analysts remain generally bullish on Pfizer’s pipeline (including obesity opportunities); investors will watch management commentary on pipeline timelines and guidance as catalysts. Read More.
• Neutral Sentiment: Pre‑market coverage flagged Pfizer among stocks to watch and dividend‑oriented trade ideas; the company’s high yield attracts income investors even as growth questions persist. Read More.
• Negative Sentiment: Commentary from TV and opinion sources questions whether Pfizer’s dividend is compelling versus fixed‑income alternatives (e.g., “If I want good yield, I’ll buy a bond”), a narrative that can pressure income‑sensitive holders and mute upside. Read More.
• Negative Sentiment: Longer‑term critiques (e.g., “priced like dead money”) highlight investor concerns about secular growth prospects and valuation, which can cap multiple expansion despite strong cash generation. Read More.

Hedge Funds Weigh In On Pfizer

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Darwin Wealth Management LLC acquired a new stake in Pfizer in the second quarter valued at $32,000. IFC & Insurance Marketing Inc. acquired a new stake in Pfizer in the fourth quarter valued at $34,000. Birchwood Financial Partners Inc. acquired a new stake in Pfizer in the fourth quarter valued at $38,000. WFA of San Diego LLC acquired a new stake in Pfizer in the second quarter valued at $40,000. Finally, Atlas Capital Advisors Inc. acquired a new stake in Pfizer in the fourth quarter valued at $41,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.